{"id":"W4387374139","doi":"10.1016/j.diabres.2023.110908","title":"Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial","year":2023,"lang":"en","type":"article","venue":"Diabetes Research and Clinical Practice","topic":"Hormonal Regulation and Hypertension","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Regeneron Pharmaceuticals; CSL Behring; Gilead Sciences; Novo Nordisk; Sanofi; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Diabetes mellitus; Type 2 diabetes; Kidney disease; Randomized controlled trial; Clinical trial; Disease; MEDLINE; Internal medicine; Physical therapy; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06356717,0.00600688,0.006621356,0.001439652,0.002818628,0.003536044,0.003679977,0.008054639,0.02612413],"category_scores_gemma":[0.05181102,0.003277802,0.004160956,0.001660522,0.005133049,0.004069674,0.001850536,0.008526503,0.009812036],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001784454,"about_ca_system_score_gemma":0.007758256,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000817893,"about_ca_topic_score_gemma":0.001708006,"domain_scores_codex":[0.9602023,0.02836652,0.002490263,0.004125696,0.002913672,0.001901424],"domain_scores_gemma":[0.9851958,0.00625807,0.002309181,0.001979871,0.001760607,0.002496468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8480666,0.01124296,0.006347525,0.02275674,0.004234378,0.001242305,0.0008403196,0.002922576,0.004082879,0.02095302,0.03013309,0.04717759],"study_design_scores_gemma":[0.8623714,0.04418493,0.004934319,0.003427882,0.004148159,0.0004229969,0.0001989796,0.00325022,0.001190922,0.01754763,0.0580977,0.0002247568],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.01446088,0.005288134,0.01152338,0.00470023,0.004127213,0.9488942,0.00400208,0.0002767905,0.006727091],"genre_scores_gemma":[0.04098043,0.001109137,0.0143442,0.005303302,0.0008810988,0.9345396,0.0009351199,0.00003261951,0.001874513],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.06356717,"threshold_uncertainty_score":0.3361794,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3141812149177413,"score_gpt":0.4790312131552177,"score_spread":0.1648499982374764,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}